3Del Dotto P,Bonuccelli U. Clinical pharmacokinetics of cabergoline[J].{H}Clinical Pharmacokinetics,2003.633-645.
4Westphal JF. Macrolide-induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4:an update focused on clarithromycin,azithromycin and dirithromycin[J].{H}British Journal of Clinical Pharmacology(England),2000.285-295.
5Ausband SC,Goodman PE. An unusual case of clarithromycin associated ergotism[J].{H}JOURNAL OF EMERGENCY MEDICINE,2001.411-413.
6Christensen J,Dupont E,Ostergaard K. Cabergoline plasma concentration is increased during concomitant treatment with itraconazole[J].{H}Movement Disorders,2002.1360-1362.
3Rinne UK,Bracco F,Chouza C,et al. Cabergoline in the treatment of early Parkinson' s disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa[J]. Neurology,1997,48(2): 363-368.
4Belanger N,Gregoire L,Tahar AH,et al. Chronic treatment with small doses of cabergoline prevents dopa-induced dyskinesias in parkinsonian monkeys[J]. Mov Disord,2003,18(12): 1436-1441.
5Pastor P,Tolosa E. Cabergoline in the treatment of Parkinson's disease[J]. Neurologia,2003,18(4): 202-209.
6Barone P. Clinical strategies to prevent and delay motor complications [J]. Neurology,2003,6 (Suppl 3): S12-16.
7Inzelberg R,Schechtman E,Nisipeanu P. Cabergoline,pramipexole and ropinirole used as monotherapy in early Parkinson ' s disease: an evidence-based comparison[J]. Drugs Aging,2003,20(11): 847-855.
8Smala AM,Spottke EA,Machat O,et al. Cabergoline versus levodopa monotherapy: a decision analysis[J]. Mov Disord,2003,18(8): 898-905.
9.Rabey JM,Nissipeanu P,Inzelberg R,et al. Beneficial effect of cabergoline,new long-lasting D2 agonist in the treatment of Parkinson' s disease[J]. Clin Neuropharmacol,1994,17(3): 286-293.
10Bhomraj T, Nelson L, Robinson T. Vascular parkinsonism-an important cause of parkinsonism in older people[ J]. Age and Ageing, 2005, 34: 114-119.
